Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment

NCT03448081 is registered in ClinicalTrials.gov with Sienna Biopharmaceuticals as lead sponsor.

NCT NCT03448081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03448081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Lead sponsor
Sienna Biopharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2018
Completion date
December 10, 2018
Enrollment
73 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

pruritus, psoriasis